Literature DB >> 4035643

Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man.

K Saku, M Ahmad, P Glas-Greenwalt, M L Kashyap.   

Abstract

The effects on fibrinolysis of purified normal human plasma lipoproteins and their apolipoproteins (apo) were assessed in an in vitro system containing urokinase, plasminogen, and fibrin. High and very low density lipoproteins (HDL and VLDL, respectively) but not low density lipoproteins (LDL) significantly increased lysis of radiolabeled fibrin or lysis area of plated fibrin compared to controls. Apo HDL, apo HDL2, apo HDL3, apo VLDL (buffer soluble apo), apo AI and AII activated fibrinolysis by 1.3-1.4 fold of control values, whereas apo B (as a narrow density cut of LDL) and non-lipoprotein control proteins (albumin and myoglobin) did not. Addition of HDL in the absence of urokinase failed to activate fibrin lysis. These data demonstrate that the major proteins of HDL - apo AI and apo AII - and possibly certain minor constituent(s) common to HDL and VLDL participate in the fibrinolytic process.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4035643     DOI: 10.1016/0049-3848(85)90116-1

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  17 in total

Review 1.  High density lipoprotein and coronary heart disease.

Authors:  D J Betteridge
Journal:  BMJ       Date:  1989-04-15

2.  Extracellular hydrophobic regions in scavenger receptor BI play a key role in mediating HDL-cholesterol transport.

Authors:  Gabriella A Papale; Kay Nicholson; Paul J Hanson; Mitja Pavlovic; Victor A Drover; Daisy Sahoo
Journal:  Arch Biochem Biophys       Date:  2010-02-26       Impact factor: 4.013

3.  Pioglitazone increases apolipoprotein A-I production by directly enhancing PPRE-dependent transcription in HepG2 cells.

Authors:  Lin-Hua Zhang; Vaijinath S Kamanna; Shobha H Ganji; Xi-Ming Xiong; Moti L Kashyap
Journal:  J Lipid Res       Date:  2010-04-06       Impact factor: 5.922

4.  Effect of clot aging and cholesterol content on ultrasound-assisted thrombolysis.

Authors:  Yufeng Zhou; Suresh Kanna Murugappan; Vijay Kumar Sharma
Journal:  Transl Stroke Res       Date:  2014-02-03       Impact factor: 6.829

Review 5.  Current, new and future treatments in dyslipidaemia and atherosclerosis.

Authors:  P H Chong; B S Bachenheimer
Journal:  Drugs       Date:  2000-07       Impact factor: 9.546

6.  Extrahepatic high-density lipoprotein receptor SR-BI and apoA-I protect against deep vein thrombosis in mice.

Authors:  Alexander Brill; Ayce Yesilaltay; Simon F De Meyer; Janka Kisucka; Tobias A Fuchs; Olivier Kocher; Monty Krieger; Denisa D Wagner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-05-31       Impact factor: 8.311

7.  Primary Low Level of High-Density Lipoprotein Cholesterol and Risks of Coronary Heart Disease, Cardiovascular Disease, and Death: Results From the Multi-Ethnic Study of Atherosclerosis.

Authors:  Haitham M Ahmed; Michael Miller; Khurram Nasir; John W McEvoy; David Herrington; Roger S Blumenthal; Michael J Blaha
Journal:  Am J Epidemiol       Date:  2016-04-18       Impact factor: 4.897

8.  Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease.

Authors:  J Aznar; A Estellés; G Tormo; P Sapena; V Tormo; S Blanch; F España
Journal:  Br Heart J       Date:  1988-05

9.  Apolipoproteins in human biopsied nephrotic kidneys.

Authors:  K Saku; T Sata; S Naito; K Fukushima; S Takebayashi; K Arakawa
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

Review 10.  Recombinant apolipoprotein A-IMilano for the treatment of cardiovascular diseases.

Authors:  Laura Calabresi; Cesare R Sirtori; Rodolfo Paoletti; Guido Franceschini
Journal:  Curr Atheroscler Rep       Date:  2006-03       Impact factor: 5.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.